GetTopicDetailResponse(id=0092e38496e, topicName=磷酸二酯酶4, introduction=磷酸二酯酶4, content=null, image=null, comments=2, allHits=1659, url=https://h5.medsci.cn/topic?id=73849, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=81652, tagList=[TagDto(tagId=81652, tagName=磷酸二酯酶4)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2118572, encodeId=053a21185e2c9, content=<a href='/topic/show?id=2120e16682b' target=_blank style='color:#2F92EE;'>#白塞氏病#</a>(BD)是一種由細(xì)胞毒性T細(xì)胞和中性粒細(xì)胞介導(dǎo)的全身性血管炎。<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>(<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>)是一種選擇性抑制<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>(PDE4)的口服小分子藥物，最近已被批準(zhǔn)用于治療BD, objectTitle=A&R：磷酸二酯酶4(PDE4)阻斷降低白塞病中性粒細(xì)胞的激活, objectType=article, longId=762155, objectId=33b8e62155d5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230309/1678295523215_5610093.png, objectUrl=/article/show_article.do?id=33b8e62155d5, replyNumber=0, likeNumber=201, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=33b8e62155d5, moduleTitle=A&R：磷酸二酯酶4(PDE4)阻斷降低白塞病中性粒細(xì)胞的激活, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=33b8e62155d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, objectTitle=磷酸二酯酶4的新型抑制劑Brilacidin治療自身免疫和炎癥疾病的潛力, objectType=article, longId=151000, objectId=6fd0151000da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fd0151000da, replyNumber=0, likeNumber=117, createdTime=2019-09-19, rootId=0, userName=醫(yī)者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fd0151000da, moduleTitle=磷酸二酯酶4的新型抑制劑Brilacidin治療自身免疫和炎癥疾病的潛力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6fd0151000da)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
